Osmotic, controlled-release methylphenidate for the treatment of ADHD.
about
Treatment of adults with attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderAssociations of sleep disturbance with ADHD: implications for treatmentImproved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.Neuroimaging with magnetoencephalography: A dynamic view of brain pathophysiology.A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in GermanyInterpreting the results of a retrospective comparison of test and reference treatments in a randomized clinical trial setting.Investigation of release pattern of a drug with low solubility through asymmetric membrane capsules.Gamma-frequency neuronal activity is diminished in adults with attention-deficit/hyperactivity disorder: a pharmaco-MEG study.Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder.
P2860
Q24642937-F17F7758-2AFC-4192-882F-4799FC6B101FQ24644586-E7A56F18-C500-4CFC-B87D-779FD25D88FBQ27027062-DE45DC52-50BC-4E6D-9B92-9F7549E83291Q35183156-08CC9184-18F3-4657-9A55-72189FFA87E7Q36469468-F971B529-3AEB-4B09-BA64-9E6A9C690DBFQ37827879-9F0616F8-242B-44BE-955C-7EDE640CA6E1Q38101134-74285FFD-B9C3-4E53-AEDF-CF55B15E8E61Q38732228-6A6DF1A7-D4A9-42F8-839E-D8C6A279D1AEQ38785464-E95CB485-C774-42DF-8D0E-F7A87741A399Q39211810-B965AA77-E82F-45BE-AC68-72BB402D75D3Q41666659-4671C12B-32AE-41D1-B02B-CA1165191B61Q42577633-8ABFDA8F-02F6-4B87-8505-40D64B332B61Q44916751-03431148-AFF8-4E34-81FB-53427FEFBAD2Q45905225-91792C89-2E03-4B51-B2E6-370C3AAFEA8AQ48283852-4899ED2A-1F17-45FA-88F0-6CA7FEB029E4Q48678229-9368A9CA-1BE2-4AF1-A7B0-8E8F08E2B761
P2860
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@ast
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@en
type
label
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@ast
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@en
prefLabel
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@ast
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@en
P2860
P1476
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
@en
P2093
David Coghill
Sarah Seth
P2860
P304
P356
10.1517/14656566.7.15.2119
P407
P577
2006-10-01T00:00:00Z